Testing a Changed Immune Cell Treatment for Children With High-Grade Glioma or DIPG
Original title: IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG)
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test to see if the treatment is safe in children.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This early study tests a treatment made from a child's own immune cells.
Who this trial is for. This study is for children with high-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary that is new or has come back, or with newly found DIPG, a brainstem tumor. The tumor must carry a certain marker, and the study tests the child's own immune cells, changed to go after that marker.
Where it stands. This study has not reported any results. It is set up to check two things. Is the treatment safe? And can it be made and given to children?
What this means, and what it doesn't
What it could mean: This is an early step in testing a new idea for these hard brain tumors. If your child has one of these tumors, you could ask the care team about this study. The trial team decides who can join.
What it doesn't mean: This is a test, not a proven treatment. Being in the study does not mean a child will be helped. It is not a cure, and no one can promise one.
Source: ClinicalTrials.gov, September 9, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.